Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. May 28, 2014; 20(20): 6092-6101
Published online May 28, 2014. doi: 10.3748/wjg.v20.i20.6092
Table 1 Comparison of treatment efficacy as a monotherapy
Clinical trialTypeTreatmentsORRPFS (mo)OS (mo)
Van Cutsem et al[12] (2001)Phase IIICapecitabine vs 5-FU/LV18.9% vs 15.0% (P = 0.013)5.2 vs 4.7 (HR = 0.96, P = 0.65)13.2 vs 12.1 (HR = 0.92, P = 0.33)
Hoff et al[11] (2001)Phase IIICapecitabine vs 5-FU/LV24.8% vs 15.5% (P = 0.005)4.3 vs 4.7 (HR = 1.03, P = 0.72)12.5 vs 13.3 (HR = 1, P = 0.97)
Van Cutsem et al[13] (2004)Integrated Analysis (Phase III)Capecitabine vs 5-FU/LV26% vs 17% (P < 0.0002)4.6 vs 4.7 (HR = 0.99, P = 0.95)12.9 vs 12.8 (HR = 0.95, P = 0.48)